DIVISLABNSEDivi's Laboratories Limited· PharmaceuticalsLowNeutral
Announced Mon, 14 Jul · 18:10 IST

Divi's Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 11, 2025

Board & Shareholder Meetings View source PDF

DIVISLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Divi's Laboratories has circulated the notice for its 35th Annual General Meeting (AGM) on August 11, 2025, at 10:00 a.m. IST, to be held via video conferencing. Key items on the agenda include adoption of FY2024-25 audited financial statements and declaration of a dividend of ₹30 per equity share (1,500% on face value of ₹2), subject to shareholder approval. The notice also seeks approval for re-appointment of two retiring directors (Ms. Nilima Prasad Divi and Dr. S. Devendra Rao), appointment of V. Bhaskara Rao & Co. as Secretarial Auditors for five years (FY2025-26 to FY2029-30), and enhancement of remuneration of Mr. Nimmagadda Venkata Anirudh, Head of Nutraceuticals and son of Executive Director Mr. N.V. Ramana, to ₹4,00,000 per month effective September 1, 2025. The record date for dividend eligibility is July 25, 2025, with payment scheduled from August 16, 2025. Remote e-voting will be open from August 7 to August 10, 2025, with the cut-off date set as August 4, 2025.

Likely market impact

The ₹30 dividend (1,500%) reflects continued strong shareholder returns from the pharma major. The related-party remuneration approval for a promoter family member is a routine compliance matter; overall, the AGM notice is procedural with no major surprises for investors.